Authors : Dr. Dina Houjjaj; Dr. Sara Mouhmouh; Dr. Fatima Zahra Belkouchi; Hachi Hafid

Volume/Issue : Volume 11 - 2026, Issue 5 - May

---

Google Scholar : https://tinyurl.com/8beu8f6p

Scribd : https://tinyurl.com/5es7duuj

DOI : https://doi.org/10.38124/ijisrt/26May1533

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : Discussion: This case illustrates the intrinsic chemoresistance of MBC and highlights the limitations of conventional therapeutic strategies. New approaches (immunotherapy, targeted therapies, ADCs) offer promising perspectives.  Conclusion: Salvage surgery remains an essential option in refractory cases. Prospective trials are needed to define optimal treatments for MBC.

Keywords : Metaplastic Carcinoma; Triple-Negative; Locally Advanced; Patey Mastectomy; Neoadjuvant Chemotherapy; Ki-67; Skin Ulceration; Chemoresistance.

References :

1. Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual malignancy with poor prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101(3):349-353.
2. Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166-173.
3. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
4. Lien HC, Lin CW, Mao TL, et al. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin. J Pathol. 2004;204(2):131-139.
5. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.
6. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast tumor cell line with BRCA2 exon 27 deletion, Her2 amplification, and PI3K pathway mutations. Cancer Res. 2009;69(3):1032-1040.
7. Benider A, Sahraoui S, Errihani H, et al. Breast cancer in Morocco: epidemiological and clinical characteristics at diagnosis. Pan Afr Med J. 2012;11:14.
8. WHO Classification of Tumours Editorial Board. Breast Tumours. 5th ed. Lyon: IARC Press; 2019.
9. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical validation of a new paradigm for perforin expression in cytotoxic cells. Appl Immunohistochem Mol Morphol. 2010;18(2):114-120.
10. Rosen PP, ed. Rosen's Breast Pathology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
11. Ross JS, Wang K, Sheehan CE, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013;19(10):2668-2676.
12. Ng CK, Schultheis AM, Bidard FC, et al. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. J Natl Cancer Inst. 2015;107(5):djv015.
13. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-715.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-3988.
15. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275-284.
16. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2015;26(Suppl 5):v8-30.
17. Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011;47(Suppl 3):S6-22.
18. Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114(1):3-10.
19. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216-1235.
20. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810-821.
21. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-2121.
22. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741-751.
23. Jhanwar-Uniyal M, Labagnara M, Friedman M, et al. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv Biol Regul. 2015;57:246-258.
24. Toft DJ, Cryns VL. Minireview: Brain storming: new frontiers in breast-brain metastasis biology. Mol Endocrinol. 2011;25(9):1447-1455.
25. Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications beyond breast cancer. Breast Cancer Res. 2018;20(1):8. © 2024 — Sidi Mohamed Ben Abdellah National Institute of Oncology, CHU Ibn Sina, Rabat, Morocco